JINGSAI
871981
HENGHE CO.,LTD.
832145
EC PERCISION
836221
CG MED EQUIP.
838810
MEIBANG TECHNOLOGY
832471
CN Stock MarketDetailed Quotes
688277 Tinavi Medical Technologies Co.,Ltd.
- 13.56
- +0.06+0.44%
Trading Mar 17 14:54 CST
6.09BMarket Cap-37.98P/E (TTM)
13.73High13.31Low53.58KlotVolume13.51Open13.50Pre Close72.59MTurnover1.19%Turnover RatioLossP/E (Static)449.39MShares15.5052wk High5.17P/B6.09BFloat Cap6.1152wk Low16.20Limit Up449.39MShs Float141.60Historical High10.80Limit Down3.11%Amplitude6.11Historical Low--Dividend TTM13.55Avg Price26.20KlotAsk--Div YieldTTM100Lot Size25.83KlotBid
Tinavi Medical Technologies Co.,Ltd. Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -31.08%92.12M | -28.81%58.31M | -26.73%28.94M | 34.48%210.04M | 58.63%133.67M | 34.41%81.92M | 130.28%39.5M | 0.11%156.19M | -19.59%84.27M | -20.23%60.95M |
| Operating revenue | -31.08%92.12M | -28.81%58.31M | -26.73%28.94M | 34.48%210.04M | 58.63%133.67M | 34.41%81.92M | 130.28%39.5M | 0.11%156.19M | -19.59%84.27M | -20.23%60.95M |
| Total operating cost | -18.05%231.02M | -16.32%156.35M | -15.52%79.86M | 27.45%424.56M | 36.59%281.91M | 38.73%186.83M | 56.13%94.53M | 14.09%333.12M | 1.03%206.39M | -0.57%134.68M |
| Operating cost | -29.44%29.99M | -35.51%18.18M | -24.47%10.68M | 13.00%60.61M | 58.29%42.5M | 48.14%28.19M | 130.00%14.14M | 7.38%53.64M | -18.52%26.85M | -7.03%19.03M |
| Operating tax surcharges | 181.03%2.82M | 150.89%1.13M | 779.22%819.53K | 377.36%2.06M | 450.86%1M | 212.82%451.77K | 269.07%93.21K | -68.10%431.46K | -78.96%181.88K | -82.45%144.42K |
| Operating expense | -27.23%69.24M | -23.55%48.36M | -28.13%22.13M | 50.83%137.86M | 85.15%95.16M | 91.37%63.26M | 90.42%30.8M | 27.97%91.4M | 2.65%51.4M | 1.81%33.05M |
| Administration expense | -8.49%51.4M | -0.09%37.15M | -16.64%18.35M | 23.29%80.79M | 12.54%56.17M | 18.31%37.18M | 32.74%22.02M | 7.49%65.53M | -5.20%49.91M | -12.92%31.42M |
| Financial expense | 1,218.74%6.91M | 449.58%3.86M | 38.46%1.99M | 672.91%2.93M | 123.01%524.21K | -80.72%-1.11M | 175.15%1.43M | 65.83%-510.97K | -6.93%-2.28M | 43.74%-611.74K |
| -Interest expense (Financial expense) | 86.37%7.11M | 179.03%4.77M | 84.06%2.32M | 62.87%6.43M | 50.33%3.82M | -3.07%1.71M | 54.61%1.26M | 17.84%3.95M | 2.58%2.54M | 10.34%1.76M |
| -Interest Income (Financial expense) | 58.53%-861.03K | 45.65%-679.94K | 38.50%-291.25K | -109.00%-2.83M | -90.67%-2.08M | -49.70%-1.25M | -7.62%-473.56K | 76.60%-1.36M | 78.39%-1.09M | 74.11%-835.75K |
| Research and development | -18.37%70.66M | -19.03%47.66M | -0.61%25.89M | 14.42%140.32M | 7.76%86.56M | 13.99%58.86M | 23.50%26.05M | 11.70%122.64M | 14.95%80.33M | 10.59%51.64M |
| Credit Impairment Loss | -13.09%-1.63M | 32.08%-1.42M | 68.06%-401.13K | -154.61%-1.38M | -1,023.57%-1.44M | -10,641.11%-2.09M | -174.20%-1.26M | 143.89%2.53M | 92.10%-128.31K | 101.48%19.8K |
| Asset Impairment Loss | -2.88%-1.48M | -232.57%-1.72M | -6.14%-196.9K | -542.21%-4.51M | -896.83%-1.44M | -436.14%-516.47K | ---185.51K | -178.32%-702.4K | -4,316.16%-144.57K | -2,773.99%-96.33K |
| Other net revenue | ||||||||||
| Fair value change income | 0.96%45.74K | 0.96%45.74K | 64.38%45.74K | -91.51%88.13K | -97.36%45.3K | -96.82%45.3K | -95.45%27.82K | 65.17%1.04M | 117.01%1.71M | 325.44%1.43M |
| Invest income | -27.63%33.13M | -30.60%33.62M | -30.81%33.59M | 6,095.44%56.13M | 3,828.88%45.78M | 5,736.18%48.44M | 7,427.59%48.55M | -131.88%-936.27K | -38.77%1.17M | -35.92%830.03K |
| -Including: Investment income associates | 13.18%-2.36M | -8,484.04%-1.66M | -3,418.27%-1.44M | 211.92%3.19M | -4,298.13%-2.72M | 21,139.57%19.79K | -39,649.99%-40.87K | -2,959,550.37%-2.85M | -49,472.06%-61.91K | 39.23%-94.04 |
| Asset deal income | 3,036,879.67%5.55M | 1,541,030.85%2.82M | ---- | 102.81%182.76 | 102.61%182.76 | 102.92%182.76 | ---- | ---6.51K | ---6.99K | ---6.26K |
| Other revenue | 10.09%6.8M | 18.14%5.63M | -48.45%2.09M | -55.59%13.8M | -70.67%6.17M | -75.04%4.76M | -38.00%4.05M | -8.45%31.07M | -14.35%21.05M | 45.91%19.09M |
| Operating profit | 2.66%-96.49M | -8.82%-59.06M | -310.75%-15.79M | -4.50%-150.4M | -0.66%-99.13M | -3.43%-54.27M | 88.67%-3.84M | -37.75%-143.93M | -33.36%-98.47M | -14.85%-52.47M |
| Add:Non operating Income | -91.36%2.33K | -66.67%2.33K | ---- | -16.96%94.8K | 440.00%27K | 40.00%7K | ---- | --114.16K | --5K | --5K |
| Less:Non operating expense | 326.33%214.95K | -34.21%33.17K | ---- | 12.78%384.34K | -85.19%50.42K | --50.42K | --50K | 100.68%340.78K | 203.58%340.47K | ---- |
| Total profit | 2.47%-96.7M | -8.79%-59.09M | -305.47%-15.79M | -4.53%-150.69M | -0.35%-99.15M | -3.52%-54.31M | 88.52%-3.89M | -37.75%-144.16M | -33.61%-98.81M | -14.72%-52.46M |
| Less:Income tax cost | 7.35%-20.53M | -0.80%-12.6M | 24.85%-5.73M | 133.34%10.61M | -100.53%-22.16M | -121.79%-12.5M | -88.33%-7.62M | -44.63%-31.82M | -13.25%-11.05M | -3.46%-5.64M |
| Net profit | 1.06%-76.17M | -11.18%-46.49M | -369.92%-10.06M | -43.58%-161.3M | 12.27%-76.99M | 10.71%-41.81M | 112.48%3.73M | -35.92%-112.34M | -36.70%-87.76M | -16.24%-46.83M |
| Net profit from continuing operation | 1.06%-76.17M | -11.18%-46.49M | -369.92%-10.06M | -43.58%-161.3M | 12.27%-76.99M | 10.71%-41.81M | 112.48%3.73M | -35.92%-112.34M | -36.70%-87.76M | -16.24%-46.83M |
| Less:Minority Profit | ---- | ---- | ---- | -180.12%-4.91M | 9.33%-4.91M | -85.50%-4.91M | -346.39%-4.91M | 35.51%-1.75M | -1,154.65%-5.42M | -67.81%-2.65M |
| Net profit of parent company owners | -5.68%-76.17M | -25.98%-46.49M | -216.49%-10.06M | -41.42%-156.39M | 12.46%-72.08M | 16.48%-36.9M | 130.03%8.64M | -38.34%-110.58M | -29.13%-82.34M | -14.14%-44.18M |
| Earning per share | ||||||||||
| Basic earning per share | -6.25%-0.17 | -25.00%-0.1 | -200.00%-0.02 | -34.62%-0.35 | 20.00%-0.16 | 27.27%-0.08 | 128.57%0.02 | -36.84%-0.26 | -33.33%-0.2 | -22.22%-0.11 |
| Diluted earning per share | -6.25%-0.17 | -25.00%-0.1 | -200.00%-0.02 | -34.62%-0.35 | 20.00%-0.16 | 27.27%-0.08 | 128.57%0.02 | -36.84%-0.26 | -33.33%-0.2 | -22.22%-0.11 |
| Other composite income | -135.96%-86.74K | -82.57%50.82K | 113.70%14.15K | -99.58%678.85K | -69.71%241.21K | -21.03%291.57K | -241.43%-103.28K | 47.76%161.34M | -60.49%796.3K | -81.43%369.24K |
| Other composite income of parent company owners | -135.96%-86.74K | -82.57%50.82K | 113.70%14.15K | -99.55%678.85K | -69.71%241.21K | -21.03%291.57K | -241.43%-103.28K | 59.17%149.53M | -34.48%796.3K | -68.92%369.24K |
| Other composite income of minority owners | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -22.54%11.81M | ---- | ---- |
| Total composite income | 0.64%-76.26M | -11.84%-46.43M | -377.22%-10.05M | -427.75%-160.62M | 11.74%-76.75M | 10.63%-41.52M | 112.12%3.62M | 84.63%49.01M | -39.85%-86.96M | -21.31%-46.46M |
| Total composite income of parent company owners | -6.15%-76.26M | -26.85%-46.43M | -217.73%-10.05M | -499.77%-155.71M | 11.90%-71.84M | 16.44%-36.61M | 129.64%8.54M | 177.93%38.95M | -30.37%-81.55M | -16.77%-43.81M |
| Total composite income of minority owners | ---- | ---- | ---- | -148.83%-4.91M | 9.33%-4.91M | -85.50%-4.91M | -346.39%-4.91M | -19.73%10.06M | -1,570.66%-5.42M | -240.43%-2.65M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Shanghui Certified Public Accountants (Special General Partnership) | -- | -- | -- | Shanghui Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
